

The mortality of epilepsy

AIDAN NELIGAN and GAIL S. BELL

UCL Institute of Neurology, Queen Square, London

It has been consistently shown in population studies that the risk of premature death is 2–3 times higher in people with epilepsy than in the general population. This mortality risk is highest in the early years following diagnosis. The risk is stratified by aetiology with patients with remote symptomatic epilepsy and neurological deficits having persistently higher risks. Other factors of relevance have been gender, age, a previous episode of status epilepticus, frequency and severity of seizures and antiepileptic drug (AED) compliance.

Long-term population-based prospective incident cohort studies provide the most reliable means of examining the risk of premature mortality and the way it changes over the course of the condition¹, although there are very few studies with follow-up of more than 20 years.

The estimates of the risk of premature death have varied between studies, and case ascertainment can be an issue depending on the methodology used. Mortality studies in epilepsy should be community-based studies of incident cohorts. Studies of people with prevalent epilepsy may underestimate the short-term mortality (as the mortality in people with epilepsy has consistently been shown to be highest in the early years following diagnosis) while simultaneously overestimating the long-term mortality (as those who have gone into remission may not be included in the cohort)². The risk of premature death in people with epilepsy has been studied using death certificates, hospital or institutional records and through follow-up of community cohorts. Death certificates have been shown to be an unreliable source, with epilepsy being recorded on the death certificate in only 7% of patients known to have had seizures³. This figure increased to 17% in those with frequent seizures. In a community-based study of mortality in children with epilepsy, epilepsy was recorded on the death certificate in 55% of deaths directly attributable to epilepsy⁴.

The most commonly reported measures of mortality in epilepsy studies comparing deaths between the study and a control population are the proportional mortality ratio (PMR) and the standardised mortality ratio (SMR). The PMR gives the proportion of deaths caused by a specific cause in the cohort and compares it with a control group. This is not a direct measure of mortality but rather gives the proportion of deaths due to one specific cause and can be influenced by the rates of other causes of death. The SMR is the ratio of the observed deaths in the study population to the expected deaths if the group had experienced the same age and sex-specific death rates as the population from which they came.

What is the risk and who is at risk?

Studies have consistently shown that males with epilepsy have higher mortality rates, with no clear explanation for this difference. The SMR tends to be high in children but this relates principally to the underlying cause of the epilepsy (remote symptomatic, perinatal insults) rather than to the epilepsy itself. The lowest SMRs are reported in the 75+ age group; this relates in part to the fact that this age group has a high mortality rate.

Few studies have looked at the risk of mortality after a single seizure. Two retrospective studies have investigated mortality after a single unprovoked seizure; one provided an SMR of 2.3 (95% confidence interval [CI] 1.5–3.3)⁵ and the other an SMR of 1.1 (95% CI 0.1–4.0) for single idiopathic seizures⁶. In the NGPSE, people with an acute symptomatic seizure (provoked seizure) had an SMR of 3.2 (CI 2.4–4.3) after more than 20 years of follow up⁷. Overall the SMR in people with a newly diagnosed unprovoked seizure ranges from 2.5 to 4.1 with the highest rates in children and those with symptomatic aetiology⁸.

Reported SMRs in mortality studies from developed countries range from 1.6 to 4.1⁹. In the Rochester study⁵, the SMR for the total group after 29 years' follow-up was 2.3, with the most significant increase in the first ten years. In the NGPSE the SMR was 2.5 after median 6.9 years with the highest SMR in the first year (5.1)¹⁰. The SMR further decreased to 2.1 after 11–14 years' follow up¹¹, and remained stable but persistently elevated after a median follow-up of 22.8 years⁷. The highest SMRs were estimated in people with remote symptomatic epilepsy (SMR 3.7; 95% CI 3.1–4.6) and epilepsy due to a congenital neurological deficit (SMR 19; 95% CI 7.0–49.7)⁷, which remained elevated throughout follow-up. In contrast people with idiopathic/cryptogenic epilepsy (defined as aetiology not determined) did not have a significantly increased long-term mortality rate (SMR 1.3; 95% CI 0.9–1.9)¹¹ in the initial stages of follow-up, a finding that has been replicated in community-based studies in Iceland⁶ and France¹². The French study, which examined the short-term mortality in people with epilepsy, is the only study to have used the categories idiopathic and cryptogenic epilepsy as defined by the ILAE, with no significant differences between the two groups. Interestingly, mortality was significantly elevated in people with idiopathic/cryptogenic epilepsy in the NGPSE during the last 10 years of follow-up⁷.

Overall, people with epilepsy have been found to have a reduction of life expectancy which is greatest at the time of diagnosis. This reduction can be up to two years in people with idiopathic/cryptogenic epilepsy and up to ten years in people with symptomatic epilepsy¹³.

Mortality in population-based studies is summarised in Table I.

Causes of death

Causes of death in people with epilepsy can be divided into epilepsy-related and non-epilepsy-related deaths. For people with symptomatic epilepsy (both remote and progressive) the excess mortality risk relates primarily to the underlying cause of the epilepsy rather than to the epilepsy itself. In a study of 692 children with epilepsy followed up over an average of 13 years, the SMR was 5.3, with functional neurological deficit being the only independent predictor of mortality (occurring in 85% of cases)¹⁴.

In a Finnish cohort of 245 children with epilepsy identified between 1961 and 1964 and followed up prospectively, 44 had died by the follow-up in 1992. Of these 75% had remote symptomatic epilepsy¹⁵ (similar to that found in childhood mortality studies from Australia⁴ and Nova Scotia¹⁴). Most (89%) of those who died were not in remission at the time of death, with a relative risk of death in those with active epilepsy compared with those in remission of 9.3 (95% CI 3.8, 22.7). The cause of death was definitely or probably related to a seizure in 45% of cases. There were three cases of sudden unexplained death in epilepsy (SUDEP) in people with idiopathic epilepsy, none of whom was in remission at the time of death¹⁵. In the extended follow-up of the cohort up to 2002, 60 (24%) had died, of whom 51 (85%) were not

in terminal remission (≥ 5 **Table I**. Population studies of mortality in people with epilepsy with standardised mortality rates (with 95% confidence intervals).

Country	SMR	Ages	Comments
Poland ³⁸	1.8	All	Retrospective prevalent cohort
United States ⁵	2.3 (1.9, 2.6)	All	Historic incident cohort (Rochester)
United States ¹⁹	2.1 (1.9, 2.5)	All	SMR for IHD elevated in those < 65 years
Iceland ⁶	1.6 (1.2, 2.2)	All	Historic incident cohort
France ¹²	4.1 (2.5, 6.2)	All	Prospective, incident cohort 1 yr mortality
Sweden ⁴⁸	2.5 (1.2, 3.2)	≥ 17 years	Prospective incident cohort with first seizure
Canada ¹⁴	5.3 (2.3, 8.3)	< 17 years	Historic incident cohort
China ⁴⁹	3.9 (3.8, 3.9)	> 2 years	Prospective prevalent cohort
United Kingdom ⁷	2.6 (2.2, 2.9)* 2.2 (2.0, 2.5)**	All	Prospective incident cohort (NGPSE) 1984-2009

*definite epilepsy

**definite and possible epilepsy

years seizure free) at the time of death. Those with a remote symptomatic aetiology were three times as likely to die as those with idiopathic/cryptogenic aetiologies (37% vs 12%). Of the 60 deaths, 33 (55%) were felt to be epilepsy related, including 18 deaths from SUDEP, giving a cumulative risk of SUDEP of 7% at 40 years (12% for those not in terminal remission and not taking AEDs¹⁶).

In a Dutch study of mortality in people with epilepsy followed for over 40 years the SMR was 16 in the first two years decreasing to 2.8 thereafter¹⁷. After two years, approximately one-third of deaths were directly or indirectly attributable to epilepsy. Common non-epilepsy causes of death cited in mortality studies include pneumonia, cerebrovascular disease, malignancy and heart disease. SMRs and PMRs are consistently elevated for these causes in population-based studies and often markedly so in the first few years of follow-up. In a Swedish study looking at cause-specific mortality in over 9000 adults with epilepsy, the overall SMR was 3.6 (95% CI 3.5–3.7), with SMRs being increased for specific causes such as cancer (SMR 2.6; 95% CI 2.4–2.8), respiratory disease (SMR 4.0; 95% CI 3.6–4.5), heart and cerebrovascular disease (SMR 3.1; 95% CI 3.0–3.3) and accidents and poisoning (SMR 5.6; 95% CI 5.0–6.3)¹⁸. The risk of premature death from heart disease in people with epilepsy was found to be elevated in those aged 25–64 but not for those aged 65 years and over in the Rochester cohort¹⁹, and also in

the NGPSE cohort during the last five years of follow-up⁷. Bronchopneumonia is an important cause of mortality in people with epilepsy of all ages, not just the elderly, and was associated with the highest SMR (6.6) in the NGPSE⁷. This may be related to aspiration during seizures but this is unproven.

The influence of mental retardation (MR) and epilepsy was investigated in a Swedish study. The SMR was 1.6 (95% CI 1.3–2.0) in people with MR only but this increased to 5.0 (95% CI 3.3–7.5) for those with MR and epilepsy, with the increase in mortality associated with seizure type and frequency²⁰. In studies from institutions and hospitals, where patients have presumably more severe epilepsy, epilepsy-related deaths are more common. In one study, PMRs were cancer (26%), bronchopneumonia (25%), circulatory diseases (24%), seizure-related deaths (other than SUDEP) (12%) and SUDEP (6%)²¹.

SMRs and PMRs for cancer have been consistently elevated in people with epilepsy even after excluding CNS neoplasms. Cancer mortality was compared between two cohorts with epilepsy, one from an institution with more severe epilepsy (SEC) and the other, a community-based population with milder epilepsy (MEC). The SMR for all cancers was elevated in the SEC (SMR 1.42; 95% CI 1.18–1.69) but not in the MEC (SMR 0.93; 95% CI 0.84–1.03). The SMR for brain and CNS neoplasms was significantly elevated in the group with milder epilepsy²².

Epilepsy-related deaths

Deaths directly related to epilepsy include SUDEP, status epilepticus, consequences of seizures (including accidents, drowning and aspiration pneumonia), iatrogenic (drug toxicity and idiosyncratic) and suicide.

The case fatality following status epilepticus typically ranges from 10–22%²³ (Rochester 21%²⁴), with some lower case fatality rates in Europe, possibly as a result of the exclusion of deaths due to status epilepticus following anoxic encephalopathy.

The primary determinant of prognosis in status epilepticus is aetiology²⁵ but other factors such as age and seizure duration are important in determining outcome²⁶. There is evidence that the case fatality following status epilepticus has been decreasing²⁷ and is particularly low in children²⁸.

SUDEP is defined as a sudden, unexpected death in an individual with or without evidence of a seizure where post-mortem does not reveal a specific cause of death²⁹. Estimates of SUDEP rates are heavily influenced by the population under study, with much higher rates in those with severe or refractory epilepsy. Identified risk factors for SUDEP include younger age of onset, long duration of epilepsy and refractory epilepsy³⁰. The incidence of SUDEP was 0.35 per 1000 person years in the Rochester cohort³¹, while an incidence of 1:295 per year was found in children with more severe epilepsy and learning difficulties³². SUDEP is reviewed in greater detail in Chapter 38.

People with epilepsy may die as a result of an accident during a seizure. Based on attendance records of four accident and emergency (A&E) departments, the risk of injury as a result of a seizure was estimated to be 29.5 per 100,000 population per year³³. Many seizure-related injuries tend to be minor, with an increased risk related to background seizure frequency³⁴, but some injuries can be fatal.

In a one-year population-based study (using inpatient records, doctors' claims and A&E visits) the annual incidence of injuries was higher in people with epilepsy, with 20.6% of people with epilepsy having at least one injury compared with 16.1% among people without epilepsy ($P < 0.001$). In particular people with epilepsy were more likely to have fractures, crushing injuries, intracranial and other head injuries³⁵. Similarly over a two-year period, people with epilepsy were more likely to have injuries inflicted on them by others (OR 1.46; 95% CI 1.04, 2.03) after adjustment for co-morbidities; they were slightly more likely to have motor vehicle accidents and completed or attempted suicide³⁶.

People with epilepsy have an increased risk of drowning (15- to 19-fold) compared with the general population. In a meta-analysis of the risk of drowning, the total SMR was 18.7. The SMR varied depending on the population under study, with an SMR of 5.4 in community-based incident cohorts, 18 in people with prevalent epilepsy, 25.7 in people with epilepsy and learning disability and 96.9 for people in institutional care³⁷.

People with epilepsy have been shown to be at increased risk of suicide in some studies^{18,38} but not in others^{5,11}. In a meta-analysis, the SMRs for suicide in people with epilepsy were markedly elevated, particularly for those with temporal lobe epilepsy³⁹. In a population-based control study from Denmark, 2.3% of people with epilepsy committed suicide compared with 0.7% in the general population, corresponding to a three-fold increased risk (risk ratio 3.2; 95% CI 2.9–3.5). This risk was particularly high in people with co-morbid psychiatric illness and in the first six months following diagnosis⁴⁰. A more recent meta-analysis found that the overall SMR for suicide in people with epilepsy was 3.3 (95% CI 2.8–3.7), with the highest rates being in those following temporal lobe excision (SMR 13.9), following other forms of epilepsy surgery (SMR 6.4) and in people with temporal lobe epilepsy (SMR 6.6)⁴¹.

AEDs and increased mortality

It has been suggested that antiepileptic treatment with more than two AEDs increases the risk of SUDEP⁴², though other studies have not shown an increased risk of SUDEP with any AED in monotherapy or in combination therapy⁴³. Moreover the risk of suicide in people taking AEDs, although increased, appears to be low⁴⁴.

It has been reported that long-term use of AEDs is associated with an increased risk of fractures, particularly in women, with the risk increasing with the duration of treatment⁴⁵.

The response to treatment has been suggested as a determinant of mortality, with people who continue to have seizures despite treatment having an increased risk of premature death compared with those rendered seizure free where no such risk was observed⁴⁶.

Non-adherence to antiepileptic medication has been shown to be associated with an over three-fold increased risk of death (hazard ratio 3.3; 95% CI 3.1–3.5) after controlling for possible confounding factors. Non-adherence was also associated with 86% increased of hospital admission and a 50% increased risk of A&E attendance⁴⁷.

Conclusions

It is clear that a diagnosis of epilepsy is associated with an increased risk of premature death, particularly in the early years following diagnosis. Up to one-third of such deaths can be

directly or indirectly attributable to epilepsy. This risk is decreased but probably not eliminated by rendering the person completely seizure free by treatment.

References

1. NELIGAN A, BELL GS, SHORVON SD et al. Temporal trends in the mortality of people with epilepsy: A review. *Epilepsia* 2010;51:2241-6.
2. LOGROSCINO G, HESDORFFER DC. Methodologic issues in studies of mortality following epilepsy: measures, types of studies, sources of cases, cohort effects, and competing risks. *Epilepsia* 2005;46 Suppl 11:3-7.
3. BELL GS, GAITATZIS A, JOHNSON AL et al. Predictive value of death certification in the case ascertainment of epilepsy. *J Neurol Neurosurg Psychiatry* 2004;75:1756-8.
4. HARVEY AS, NOLAN T, CARLIN JB. Community-based study of mortality in children with epilepsy. *Epilepsia* 1993;34:597-603.
5. HAUSER WA, ANNEGERS JF, ELVEBACK LR. Mortality in patients with epilepsy. *Epilepsia* 1980;21:399-412.
6. OLAFSSON E, HAUSER WA, GUDMUNDSSON G. Long-term survival of people with unprovoked seizures: a population-based study. *Epilepsia* 1998;39:89-92.
7. NELIGAN A, BELL GS, JOHNSON AL et al. The long-term risk of premature mortality in people with epilepsy. *Brain* 2011;134:388-95.
8. HAUSER WA, BEGHI E. First seizure definitions and worldwide incidence and mortality. *Epilepsia* 2008;49 Suppl 1:8-12.
9. FORSGREN L, HAUSER WA, OLAFSSON E et al. Mortality of epilepsy in developed countries: a review. *Epilepsia* 2005;46 Suppl 11:18-27.
10. COCKERELL OC, JOHNSON AL, SANDER JW et al. Mortality from epilepsy: results from a prospective population-based study. *Lancet* 1994;344:918-21.
11. LHATOO SD, JOHNSON AL, GOODRIDGE DM et al. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. *Ann Neurol* 2001;49:336-44.
12. LOISEAU J, PICOT MC, LOISEAU P. Short-term mortality after a first epileptic seizure: a population-based study. *Epilepsia* 1999;40:1388-92.
13. GAITATZIS A, JOHNSON AL, CHADWICK DW et al. Life expectancy in people with newly diagnosed epilepsy. *Brain* 2004;127:2427-32.
14. CAMFIELD CS, CAMFIELD PR, VEUGELERS PJ. Death in children with epilepsy: a population-based study. *Lancet* 2002;359:1891-5.
15. SILLANPAA M, JALAVA M, KALEVA O et al. Long-term prognosis of seizures with onset in childhood. *N Engl J Med* 1998;338:1715-22.
16. SILLANPAA M, SHINNAR S. Long-Term mortality in childhood-onset epilepsy. *N Engl J Med* 2010;363:2522-9.
17. SHACKLETON DP, WESTENDORP RG, TRENITE DG et al. Mortality in patients with epilepsy: 40 years of follow up in a Dutch cohort study. *J Neurol Neurosurg Psychiatry* 1999;66:636-40.
18. NILSSON L, TOMSON T, FARAHMAND BY et al. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. *Epilepsia* 1997;38:1062-8.
19. ANNEGERS JF, HAUSER WA, SHIRTS SB. Heart disease mortality and morbidity in patients with epilepsy. *Epilepsia* 1984;25:699-704.
20. FORSGREN L, EDVINSSON SO, NYSTROM L et al. Influence of epilepsy on mortality in mental retardation: an epidemiologic study. *Epilepsia* 1996;37:956-63.
21. KLENERMAN P, SANDER JW, SHORVON SD. Mortality in patients with epilepsy: a study of patients in long term residential care. *J Neurol Neurosurg Psychiatry* 1993;56:149-52.
22. SINGH G, FLETCHER O, BELL GS et al. Cancer mortality amongst people with epilepsy: a study of two cohorts with severe and presumed milder epilepsy. *Epilepsy Res* 2009;83:190-7.
23. LOGROSCINO G, HESDORFFER DC, CASCINO G et al. Mortality after a first episode of status epilepticus in the United States and Europe. *Epilepsia* 2005;46 Suppl 11:46-8.
24. DELORENZO RJ, HAUSER WA, TOWNE AR et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. *Neurology* 1996;46:1029-35.
25. NELIGAN A, SHORVON SD. Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. *Arch Neurol* 2010;67:931-40.
26. NELIGAN A, SHORVON SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: A review. *Epilepsy Res* 2011;93:1-10.
27. WU YW, SHEK DW, GARCIA PA et al. Incidence and mortality of generalized convulsive status epilepticus in California. *Neurology* 2002;58:1070-6.
28. CHIN RF, NEVILLE BG, PECKHAM C et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. *Lancet* 2006;368:222-9.
29. NASHEF L. Sudden Unexpected Death in Epilepsy: terminology and definitions. *Epilepsia* 1997;38; Suppl 11:6-8.
30. TOMSON T, WALCZAK T, SILLANPAA M et al. Sudden unexpected death in epilepsy: a review of incidence and risk factors. *Epilepsia* 2005;46 Suppl 11:54-61.
31. FICKER DM, SO EL, SHEN WK et al. Population-based study of the incidence of sudden unexplained death in epilepsy. *Neurology* 1998;51:1270-4.

32. NASHEF L, FISH DR, GARNER S et al. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. *Epilepsia* 1995;36:1187-94.
33. KIRBY S, SADLER RM. Injury and death as a result of seizures. *Epilepsia* 1995;36:25-8.
34. LAWN ND, BAMLET WR, RADHAKRISHNAN K et al. Injuries due to seizures in persons with epilepsy: a population-based study. *Neurology* 2004;63:1565-70.
35. KWON CS, LIU M, QUAN H et al. The incidence of injuries in persons with and without epilepsy – a population-based study. *Epilepsia*. 2010;51:2247-53.
36. KWON C, LIU M, QUAN H et al. Motor vehicle accidents, suicides, and assaults in epilepsy: A population-based study. *Neurology* 2011;76:801-6.
37. BELL GS, GAITATZIS A, BELL CL et al. Drowning in people with epilepsy: how great is the risk? *Neurology* 2008;71:578-82.
38. ZIELINSKI JJ. Epilepsy and mortality rate and cause of death. *Epilepsia* 1974;15:191-201.
39. HARRIS EC, BARRACLOUGH B. Suicide as an outcome for mental disorders. A meta-analysis. *Br J Psychiatry* 1997;170:205-28.
40. CHRISTENSEN J, VESTERGAARD M, MORTENSEN PB et al. Epilepsy and risk of suicide: a population based case-control study. *Lancet Neurol* 2007;6:693-8.
41. BELL GS, GAITATZIS A, BELL CL et al. Suicide in people with epilepsy: how great is the risk? *Epilepsia* 2009;50:1933-42.
42. WALCZAK TS, LEPPIK IE, D'AMELIO M et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. *Neurology* 2001;56:519-25.
43. OPESKIN K, BERKOVIC SF. Risk factors for sudden unexpected death in epilepsy: a controlled prospective study based on coroners cases. *Seizure* 2003;12:456-64.
44. BELL GS, MULA M, SANDER JW. Suicidality in people taking antiepileptic drugs: what is the evidence? *CNS Drugs* 2009;23:281-92.
45. SOUVEREIN PC, WEBB DJ, WEIL JG et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. *Neurology* 2006;66:1318-24.
46. MOHANRAJ R, NORRIE J, STEPHEN LJ et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. *Lancet Neurol* 2006;5:481-7.
47. FAUGHT E, DUH MS, WEINER JR et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. *Neurology* 2008;71:1572-8.
48. LINDSTEN H, NYSTRÖM L, FORSGREN L. Mortality risk in an adult cohort with a newly diagnosed unprovoked epileptic seizure: a population-based study. *Epilepsia* 2000;41:1469-73.
49. DING D, WANG W, WU J et al. Premature mortality in people with epilepsy in rural China: a prospective study. *Lancet Neurol* 2006;5:823-7.